CenTrial Logo

Customized Lenses for Outward Eye Deviation Shows Promising Results in Clinical Trial

by


Customized lens therapy improves outward eye deviation clinical trial shows

Intermittent exotropia (IXT) is a common eye condition that affects both children and adults. It is characterized by the intermittent outward deviation of one eye while the other eye remains straight. This misalignment can cause double vision and eye strain, leading to discomfort and difficulties in daily activities such as reading and driving.

IXT is caused by a weakness in the eye muscles responsible for controlling eye movement and can be aggravated by factors such as fatigue, illness, and stress. While the condition can improve on its own or with non-surgical treatments such as glasses and eye exercises, some cases may require surgical intervention. Early diagnosis and treatment can help prevent complications and improve visual outcomes. In a clinical trial, researchers evaluated the efficacy of a new algorithm to customize overminus lens (OML) therapy in children with IXT.

Clinical trial

The study included 141 children between the ages of 4 and 15 with IXT. They were randomly assigned to either the OML or the observation group. The observation group was only corrected for significant refractive errors, while the OML group received customized lenses based on their individual physiological factors. The OML power ranged between -1.00D and -6.25D.

The researchers examined the participants' IXT control score, angle of deviation, refraction, axial length, and stereopsis at baseline and follow-up visits between 6 and 15 months. Compliance and tolerance to OML were also assessed through a symptom survey.

Results

The results showed that OML therapy was highly effective in improving distance control, angle of deviation, and stereopsis in children with IXT. The IXT control score improved significantly in the OML group, with a mean difference of -2.5 ± 1.1 (p < 0.001), while the angle of deviation reduced by 6.9 ± 7.2pd (p < 0.001).

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me

The compliance rate to OML wear was 80%, and 90% of participants never or rarely experienced asthenopia symptoms (ocular fatigue, discomfort, lacrimation, headache). Although there was a slightly greater myopic shift and change in axial length in the OML group, these differences were not statistically significant.

Overall, the findings suggest that a customized OML, calculated using this novel algorithm, can be an effective treatment option for improving the symptoms of IXT in children. It's also well-tolerated and highly compliant, which is crucial for any long-term treatment plan.

The study highlights the importance of considering individual physiological factors when designing treatment plans for IXT. By tailoring the treatment to each child's unique needs, it's possible to achieve better outcomes and improve their quality of life.

Conclusion

This study provides promising results for the use of a novel algorithm to customize OML therapy for children with IXT. It's a safe, effective, and well-tolerated treatment option that can significantly improve the symptoms of this condition. If your child has IXT, it's worth discussing this treatment option with your eye care professional to see if it's appropriate for them.

__________



Share this article with a friend:
     


Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

20,000 clinical trials are seeking participants.
Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.


This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.